We also found that CD8+ depletion/anti-PD-1 treatment caused mild decrease (insignificant) of anti-tumor immunity for Hepa1-6 (normalized enrichment score (NES) < 1, Fig. 4C), while severe decrease of anti-tumor immunity for MC38 (NES > 1.5, p < 0.05 compared to anti-PD-1 treatment) per downregulation of major immune response gene pathways (Fig. 3C). The gene discussed is CD8A; the disease is neoplasm.